Publications

• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
  Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221–1229.
• Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies
  Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., … Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187–5194.
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
  Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., … Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078–1086.
• Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy Advani, R., Rosenberg, S. A., & Horning, S. J. (2004). Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. JOURNAL OF CLINICAL ONCOLOGY, 22(8), 1454–1459.
  
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968–1973.
  
• A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., … Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467–477.
  
• Management of advanced stage Hodgkin lymphoma. Advani, R., Ai, W. Z., & Horning, S. J. (2006). Management of advanced stage Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 4(3), 241–247.
  
• Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., Dick, S., … Kim, Y. H. (2006). Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. ARCHIVES OF DERMATOLOGY, 142(5), 577–584.
  
• Treatment of mantle cell lymphoma: Current approach and future directions Brody, J., & Advani, R. (2006). Treatment of mantle cell lymphoma: Current approach and future directions. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 58(3), 257–265.
  
• Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine Advani, R., Horwitz, S., Zelenetz, A., & Horning, S. J. (2007). Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. LEUKEMIA & LYMPHOMA, 48(3), 521–525.
  
• Non-Hodgkin lymphoma of the breast Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., & Horning, S. (2007). Non-Hodgkin lymphoma of the breast. CANCER, 110(1), 25–30.
  
• 
  
• Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Chen, A. I., & Advani, R. H. (2008). Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Journal of the National Comprehensive Cancer Network , 6(4), 428–435.
  
• 
  
• Hodgkin disease/lymphoma. Hoppe, R. T., Advani, R. H., Ambinder, R. F., Bierman, P. J., Bloomfield, C. D., Blum, K., … Zelenetz, A. D. (2008). Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network , 6(6), 594–622.
  
• Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–957.
  
• Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Alizadeh, A. A., & Advani, R. H. (2008). Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clinical Advances in Hematology & Oncology : H&O, 6(12), 899–909.
  
• Targeting CD40 in Waldenstrom's Macroglobulinemia Lee, M., & Advani, R. (2009). Targeting CD40 in Waldenstrom's Macroglobulinemia. CLINICAL LYMPHOMA & MYELOMA, 9(1), 87–89.
  
• 
  
• The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma Maeda, L. S., & Advani, R. H. (2009). The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. CURRENT OPINION IN ONCOLOGY, 21(5), 397–400.
  
• 
  
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Horning, S. J., Juweid, M. E., Schoeder, H., Wiseman, G., McMillan, A., Swinnen, L. J., … Quon, A. (2010). Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. BLOOD, 115(4), 775–777.
  
• 
  
• Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment Kohrt, H., & Advani, R. (2009). Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. LEUKEMIA & LYMPHOMA, 50(11), 1773–1784.
  
• 
  
• Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., Wakelee, H. A., … Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167–2175.
  
• Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., … Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971–77.
  
• 
  
• Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI) Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. A., Fisher, R. I., … Horning, S. J. (2010). Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). BRITISH JOURNAL OF HAEMATOLOGY, 151(2), 143–151.
  
• Risk stratification in extranodal natural killer/T-cell lymphoma Kohrt, H., Lee, M., & Advani, R. (2010). Risk stratification in extranodal natural killer/T-cell lymphoma. EXPERT REVIEW OF ANTICANCER THERAPY, 10(9), 1395–1405.
  
• 
  
• CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma Burington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., Tan, J., … Dornan, D. (2011). CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 3(74).
  
• 
  
• 
  
• Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., … Levy, R. (2011). Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. BLOOD, 118(5), 1350–1358.
  
• Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus Thuong-Thuong Nguyen, T. T., Gubens, M., Arber, D. A., Advani, R., Juretzka, M., & Aziz, N. (2011). Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus. OBSTETRICS AND GYNECOLOGY, 118(2), 486–489.
  
• 
  
• 
  
• Optimal therapy of advanced Hodgkin lymphoma. Advani, R. (2011). Optimal therapy of advanced Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011, 310–316.
  
• 
  
• 
  
• Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. (2012). Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2190–2196.
  
• Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R. D., Paietta, E., Forero-Torres, A., … Horning, S. J. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. JOURNAL OF CLINICAL ONCOLOGY, 30(25), 3119–3126.
  
• Cancer Vaccines and T Cell Therapy Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97–S101.
  
• Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., … Fowler, N. H. (2013). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(1), 88–94.
  
• 
  
• Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma Scott, D. W., Chan, F. C., Hong, F., Rogic, S., Tan, K. L., Meissner, B., … Gascoyne, R. D. (2013). Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 692–700.
  
• 
  
• 
  
• A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. (2005). Investigational New Drugs, In Press.
  
• Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). (1999). Blood, 93.
  
• 
  
• PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., … Humerickhouse, R. (2010). PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES. Presented at the 15th Annual Meeting of the European-Hematology-Association, BARCELONA,SPAIN: FERRATA STORTI FOUNDATION.
  
• Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies Kahl, B., Roberts, A. W., Seymour, J. F., Advani, R. H., Persky, D. O., Yang, J., … Humerickhouse, R. (2010). Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies. BLOOD, 116(21), 1608–1608.
  
• Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009 Kwong, Y.-L., Anderson, B. O., Advani, R., Kim, W.-S., Levine, A. M., & Lim, S.-T. (2009). Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. LANCET ONCOLOGY, 10(11), 1093–1101.
  
• 
  
• 
  
• 
  
• OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS YARBER, J. L., Otis, S. A., Robinson, B. K., Gordon, L. I., Winter, J. N., Advani, R. H., & Evens, A. M. (2011). OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
  
• Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis Evens, A. M., Advani, R., Lossos, I. S., Press, O. W., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2011). Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. BLOOD, 118(21), 45–46.
  
• Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia Treon, S. P., Tripsas, C. K., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., … Ghobrial, I. M. (2011). Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1273–1274.
  
• A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Furman, R. R., Eradat, H., DiRienzo, C. G., Hayman, S. R., Hofmeister, C. C., Avignon, N. A., … Lin, T. S. (2011). A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1581–1581.
  
• ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II Das, P., Ng, A., Constine, L. S., Advani, R., Flowers, C., Friedberg, J., … Yunes, M. J. (2011). ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 8(5), 302–308.
  
• 
  
• 
  
• Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676] Brody, J. D., Ai, W. Z., Czerwinski, D. K., Advani, R., Horning, S. J., Hoppe, R. T., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676]. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
  
• 
  
• LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., … Natkunam, Y. (2008). LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. BLOOD, 112(11), 1291–1291.
  
• 
  
• Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP) Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., … Natkunam, Y. (2009). Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• 
  
• 
  
• 
  
• 
  
• Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909 Brody, J., Ai, W. Z., Czerwinski, D., Advani, R., Horning, S. J., Ganjoo, K. N., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  
• in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses Czerwinski, D. K., Brody, J., Kohrt, H. E., Hoppe, R. T., Advani, R. H., & Levy, R. (2012). in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. BLOOD, 120(21).
  
• The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., & Horning, S. J. (2009). The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. BLOOD, 114(22), 663–663.
  
• PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R., Paietta, E., Forero-Torres, A., … Horning, S. (2011). PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND: OXFORD UNIV PRESS.
  
• Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Advani, R. H., Hong, F., Li, H., Kahl, B. S., Pfreundschuh, M., & Ziepert, M. (2011). Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). BLOOD, 118(21), 681–681.
  
• Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years Advani, R. H., Li, H., Hoppe, R. T., Bartlett, N. L., Bennett, J. M., Neuberg, D. S., … Horning, S. J. (2012). Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. BLOOD, 120(21).
  
• Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Yang, D. T., Paietta, E., … Horning, S. J. (2012). Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. BLOOD, 120(21).
  
• Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). Smith, M. R., Chen, H., Gordon, L., Foran, J., Kahl, B., Advani, R., … Horning, S. J. (2006). Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). JOURNAL OF CLINICAL ONCOLOGY, 24(18), 422S–422S.
  
• Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499 Smith, M. R., Zhang, L., Gordon, L. I., Foran, J., Kahl, B., Gascoyne, R. D., … Horning, S. J. (2007). Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499. BLOOD, 110(11), 121A–121A.
  
• Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial Foss, F., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M., … Acosta, M. (2007). Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial. BLOOD, 110(11), 1011A–1011A.
  
• Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(3), 288–334.
  
• 
  
• Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). Kahl, B. S., Advani, R., Kay, N., Lossos, I. S., Evens, A., Gordon, L., … Phan, S. C. (2005). Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). BLOOD, 106(11), 269B–270B.
  
• Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression Krathen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., Wood, G. S., … Kim, Y. H. (2012). Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. BLOOD, 120(21).
  
• Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., Sadan, S., … Horwitz, S. M. (2005). Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. BLOOD, 106(11), 934A–934A.
  
• Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., Advani, R., … Kim, Y. (2007). Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome. BLOOD, 110(11), 1045A–1045A.
  
• CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. Dornan, D., Burington, B., Yue, P., Shi, X., Advani, R., Yu, N., … Ebens, A. J. (2009). CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. BLOOD, 114(22), 1065–1065.
  
• 
  
• 
  
• The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial Wang, L., Martin, P., Blum, K. A., Kahl, B. S., Maeda, L. S., Advani, R., … Goy, A. (2011). The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. BLOOD, 118(21), 203–204.
  
• Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. Maeda, L. S., Geiger, J. L., Savage, K. J., Rose, J., Pinter-Brown, L. C., Lunning, M. A., … Advani, R. (2012). Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• 
  
• A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Advani, R., Lebmic, D., Brunvand, M., Chen, A. I., Goy, A., Chang, J. E., … Cheson, B. D. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
  
• Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., … Rowe, J. M. (1999). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). BLOOD, 94(10), 383A–383A.
  
• A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. Pollyea, D. A., Smith, S., Fowler, N., Boyd, T. E., Smith, A. M., Sirisawad, M., … Advani, R. (2009). A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. BLOOD, 114(22), 1430–1430.
  
• 
  
• Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma Rubenstein, J. L., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., … Damon, L. E. (2011). Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. BLOOD, 118(21), 438–439.
  
• A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., & Sikic, B. (2005). A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 234S–234S.
  
• A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Palanca-Wessels, M. C., Flinn, I. W., Sehn, L. H., Patel, M., Sangha, R., Czuczman, M. S., … Assouline, S. E. (2012). A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
  
• Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels Bashey, S., Krathen, M., Sutherland, K., Sundram, U., Lingala, B., Horwitz, S., … Kim, Y. (2012). Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels. Presented at the 75th Annual Meeting of the Society-for-Investigative-Dermatology, RALEIGH,NC: NATURE PUBLISHING GROUP.
  
• Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 Advani, R., Hong, F., Gordon, L. I., Gascoyne, R. D., Wagner, H., Hoppe, R. T., … Horning, S. J. (2011). Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. BLOOD, 118(21), 696–697.
  
• A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., … Bartlett, N. L. (2012). A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. CLINICAL CANCER RESEARCH, 18(1), 248–255.
  
• Hodgkin lymphoma. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., … Yahalom, J. (2011). Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 9(9), 1020–58.
  
• Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Hoppe, R. T., Advani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F., Djulgegovic, B., … Zelenetz, A. D. (2006). Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 210–230.
  
• Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., Bartlett, N. L., … Gascoyne, R. D. (2012). Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. BLOOD, 120(16), 3280–3287.
  
• Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies Forero-Torres, A., Fanale, M., Advani, R., Bartlett, N. L., Rosenblatt, J. D., Kennedy, D. A., & Younes, A. (2012). Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. ONCOLOGIST, 17(8), 1073–1080.
  
• Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2012). Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(5), 589–597.
  
• Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W.-S., Hong, F., … Ambinder, R. F. (2013). Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood, 121(18), 3547–3553.
  
• The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., … Horning, S. J. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. BRITISH JOURNAL OF HAEMATOLOGY, 161(1), 76–86.
  
• Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., … Duvic, M. (2011). Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 64(2), 352–404.
  
• 
  
• Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., … Damon, L. E. (2013). Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. BLOOD, 121(5), 745–51.
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., Schwartz, E. J., … Wakelee, H. A. (2004). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 248S–248S.
  
• 
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., … Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S–6103S.
  
• 
  
• 
  
• Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., Belt, R., … Foss, F. (2007). Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study. BLOOD, 110(11), 1012A–1012A.
  
• Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Forero-Torres, A., Berryman, R. B., Advani, R. H., Bartlett, N. L., Chen, R. W., Fanale, M. A., … Matous, J. (2011). Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). BLOOD, 118(21), 1585–1586.
  
• Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas Illidge, T., Bouabdallah, R., Chen, R. W., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. H. (2011). Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas. BLOOD, 118(21), 1335–1336.
  
• Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas Fanale, M. A., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Horwitz, S. M. (2012). Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas. BLOOD, 120(21).
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. Advani, R. H., Hoppe, R. T., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2009). Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. BLOOD, 114(22), 666–667.
  
• 
  
• 
  
• Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. Treon, S., Hunter, Z. R., Matous, J., Badros, A., Joyce, R. M., Mannion, B., … Patterson, C. J. (2005). Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. BLOOD, 106(11), 147A–147A.
  
• Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248 Treon, S. P., Hunter, Z. R., Matous, J., Joyce, R. M., Mannion, B., Advani, R., … Badros, A. (2007). Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248. CLINICAL CANCER RESEARCH, 13(11), 3320–3325.
  
• ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma. ONCOLOGY-NEW YORK, 27(8), 786–794.
  
• 
  
• 
  
• Targeted Therapy in Relapsed Classical Hodgkin Lymphoma Dinner, S., & Advani, R. (2013). Targeted Therapy in Relapsed Classical Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 968–976.
  
• Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., … Zafar, N. (2011). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(5), 484–560.
  
• A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study Foss, F. M., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M. R., … Bolejack, V. (2013). A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. LEUKEMIA & LYMPHOMA, 54(7), 1373–1379.
  
• Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Aalipour, A., & Advani, R. H. (2013). Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. British Journal of Haematology, 163(4), 436–443.
  
• Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines Tan, D., Tan, S. Y., Lim, S. T., Kim, S. J., Kim, W.-S., Advani, R., & Kwong, Y.-L. (2013). Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. LANCET ONCOLOGY, 14(12), E548–E561.
  
• Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–4139.
  
• 
  
• Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Zelenetz, A. D., Advani, R. H., Buadi, F., Cabanillas, F., Caligiuri, M. A., Czuczman, M. S., … Yahalom, J. (2006). Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 258–310.
  
• Non-Hodgkin's Lymphomas, version 3.2012. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network , 10(12), 1487–1498.
  
• Non-Hodgkin's lymphomas. Zelenetz, A. D., Advani, R. H., Byrd, J. C., Czuczman, M. S., Damon, L. E., Duvic, M., … Yunus, F. (2008). Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 6(4), 356–421.
  
• Non-Hodgkin's lymphomas, version 1.2013. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network , 11(3), 257–272.
  
• NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 8(3), 288–334.
  
• 
  
• 
  
• Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology, 7, 24-?
  
• ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Terezakis, S. A., Metzger, M. L., Hodgson, D. C., Schwartz, C. L., Advani, R., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer, 61(7), 1305–1312.
  
• ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma Ng, A., Constine, L. S., Advani, R., Das, P., Flowers, C., Friedberg, J., … Yunes, M. J. (2010). ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma. CURRENT PROBLEMS IN CANCER, 34(3), 211–227.
  
• A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era Hosein, P. J., Maragulia, J. C., Salzberg, M. P., Press, O. W., Habermann, T. M., Vose, J. M., … Lossos, I. S. (2014). A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. BRITISH JOURNAL OF HAEMATOLOGY, 165(3), 358–363.
  
• Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E. M., Yang, D. T., … Kahl, B. S. (2014). Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood, 123(11), 1665–1673.
  
• Non-Hodgkin's lymphomas, version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–946.
  
• A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
  
• 
  
• Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–4139.
  
• Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
  
• ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park, N.Y.), 27(8), 786–794.
  
• A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology, 7, 44-?
  
• Non-Hodgkin's Lymphomas, Version 4.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network , 12(9), 1282–1303.
  
• Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study. JOURNAL OF CLINICAL ONCOLOGY, 32(28), 3137-?
  
• ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 11(11), 1026–1033.
  
• Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Garfin, P. M., Link, M. P., Donaldson, S. S., Advani, R. H., Luna-Fineman, S., Kharbanda, S., … Agarwal-Hashmi, R. (2015). Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Biology of Blood and Marrow Transplantation , 21(2), 326–334.
  
• Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Aalipour, A., & Advani, R. H. (2014). Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology, 5(4), 121–133.
  
• Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Journal of Clinical Oncology , 33(7), 740–748.
  
• Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
  
• Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., … Hoppe, R. T. (2015). Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology, Biology, Physics, 92(1), 99–106.
  
• Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era King, M. T., Donaldson, S. S., Link, M. P., Natkunam, Y., Advani, R. H., & Hoppe, R. T. (2015). Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 92(1), 67–75.
  
• 
  
• 
  
• Optimal Therapy of Advanced Hodgkin Lymphoma Advani, R. (2011). Optimal Therapy of Advanced Hodgkin Lymphoma. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 310–316.
  
• How I treat nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2013). How I treat nodular lymphocyte predominant Hodgkin lymphoma. BLOOD, 122(26), 4182–4188.
  
• Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Gopal, A. K., Ramchandren, R., O'Connor, O. A., Berryman, R. B., Advani, R. H., Chen, R., … Zain, J. (2012). Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. BLOOD, 120(3), 560–568.
  
• Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O'Connor, O. A., … Oki, Y. (2014). Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. BLOOD, 123(20), 3095–3100.
  
• Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? Diefenbach, C., & Advani, R. (2014). Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 28(1), 105-?
  
• Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., … Bartlett, N. L. (2015). Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. BLOOD, 125(9), 1394–1402.
  
• A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., … Pohlman, B. (2015). A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 168(6), 811–819.
  
• Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma Illidge, T., Bouabdallah, R., Chen, R., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. (2015). Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. LEUKEMIA & LYMPHOMA, 56(3), 703–710.
  
• Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus Dimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., … Treon, S. P. (2014). Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. BLOOD, 124(9), 1404–1411.
  
• Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies Marostica, E., Sukbuntherng, J., Loury, D., de Jong, J., de Trixhe, X. W., Vermeulen, A., … Poggesi, I. (2015). Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 75(1), 111–121.
  
• Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies Han, T. H., Chen, R., Advani, R., Berryman, R. B., Smith, S. E., Forero-Torres, A., … Engert, A. (2013). Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 72(1), 241–249.
  
• Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of Clinical Oncology , 32(28), 3137–3143.
  
• 
  
• 
  
• Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404) Swinnen, L. J., Li, H., Quon, A., Gascoyne, R., Hong, F., Ranheim, E. A., … Advani, R. H. (2015). Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). BRITISH JOURNAL OF HAEMATOLOGY, 170(1), 56–65.
  
• Management of nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2015). Management of nodular lymphocyte predominant Hodgkin lymphoma. HEMATOLOGICAL ONCOLOGY, 33, 90–95.
  
• Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., … Horning, S. J. (2015). Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology , 33(17), 1936–1942.
  
• Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., … Morschhauser, F. (2015). Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. LANCET ONCOLOGY, 16(6), 704–715.
  
• 
  
• Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., … Lenz, G. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia, 29(7), 1578–1586.
  
• Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies Roberts, A. W., Advani, R. H., Kahl, B. S., Persky, D., Sweetenham, J. W., Carney, D. A., … Seymour, J. F. (2015). Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 669–678.
  
• 
  
• A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402 Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., … Horning, S. J. (2015). A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 679–686.
  
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., … Staudt, L. M. (2015). Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. NATURE MEDICINE, 21(8), 922–926.
  
• Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. AMERICAN JOURNAL OF HEMATOLOGY, 90(9), 778–783.
  
• Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Journal of Clinical Oncology , 32(9), 912–918.
  
• 
  
• Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT) Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). JOURNAL OF CLINICAL ONCOLOGY, 33(7).
  
• Non-Hodgkin's Lymphomas, Version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–946.
  
• Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Current Treatment Options in Oncology, 16(9), 360-?
  
• ACR appropriateness criteria follow-up of Hodgkin lymphoma. Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness criteria follow-up of Hodgkin lymphoma. Journal of the American College of Radiology , 11(11), 1026–1033 e3.
  
• Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 90(9), 778–783.
  
• 
  
• Postibrutinib outcomes in patients with mantle cell lymphoma Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., … Blum, K. A. (2016). Postibrutinib outcomes in patients with mantle cell lymphoma. BLOOD, 127(12), 1559–1563.
  
• ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. Dabaja, B. S., Advani, R., Hodgson, D. C., Dhakal, S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2015). ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. American Journal of Clinical Oncology, 38(6), 610–620.
  
• 
  
• Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
  
• Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–3758.
  
• Intra-CSF rituximab for lymhomatous meningitis - Reply Rubenstein, J., Abrey, L., Advani, R., Shuman, M., Tsai, T., & O'Brien, J. (2007). Intra-CSF rituximab for lymhomatous meningitis - Reply. JOURNAL OF CLINICAL ONCOLOGY, 25(28), 4509–4511.
  
• 
  
• Speeding up PET/MR for cancer staging of children and young adults. Aghighi, M., Pisani, L. J., Sun, Z., Klenk, C., Madnawat, H., Fineman, S. L., … Daldrup-Link, H. E. (2016). Speeding up PET/MR for cancer staging of children and young adults. European Radiology, -?
  
• Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., … Lossos, I. S. (2016). Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood, 128(2), 239–248.
  
• A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis Kim, S. J., Yoon, D. H., Jaccard, A., Chng, W. J., Lim, S. T., Hong, H., … Kim, W. S. (2016). A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. LANCET ONCOLOGY, 17(3), 389–400.
  
• 
  
• A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Advani, R. H., Ansell, S. M., Lechowicz, M. J., Beaven, A. W., Loberiza, F., Carson, K. R., … M Vose, J. (2016). A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. British Journal of Haematology, 172(4), 535–544.
  
• Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., … Drachman, J. G. (2015). Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia & Lymphoma, 56(9), 2569–78.
  
• 
  
• A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leukemia & Lymphoma, 57(3), 604–608.
  
• 
  
• Diffuse Large B-Cell Lymphoma Version 1.2016. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016. Journal of the National Comprehensive Cancer Network , 14(2), 196–231.
  
• Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1228–1230.
  
• Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1225–1227.
  
• Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., … Quon, A. (2016). Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. RADIOLOGY, 280(1), 220–229.
  
• 
  
• Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Castillo, J. J., Palomba, M. L., Advani, R., & Treon, S. P. (2016). Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 7(4), 179–186.
  
• 2 Gy?×?2 for palliative treatment of mantle cell lymphoma. White, E. C., Advani, R., & Hoppe, R. T. (2016). 2 Gy?×?2 for palliative treatment of mantle cell lymphoma. Leukemia & Lymphoma, 57(9), 2219–2221.
  
• 
  
• ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Roberts, K. B., Younes, A., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., … Constine, L. S. (2016). ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology, 39(4), 384–395.
  
• 
  
• Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., … Dimopoulos, M. A. (2016). Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 128(10), 1321–1328.
  
• NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network , 14(9), 1067–79.
  
• 
  
• Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., … Rodig, S. J. (2016). Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 4(11), 910–916.
  
• Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., … Kahl, B. S. (2016). Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia.
  
• 
  
• Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Demos, M., … Treon, S. P. (2017). Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Blood.
  
• Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., … Cheson, B. D. (2017). Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(5), 1167–76.
  
• Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., … Armand, P. (2016). Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. BLOOD, 128(21), 2489–2496.
  
• 
  
• 
  
• Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Furman, R. R., Eradat, H. A., DiRienzo, C. G., Hofmeister, C. C., Hayman, S. R., Leonard, J. P., … Lin, T. S. (2017). Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology, 4(1), e24–e34.
  
• 
  
• The landscape of new drugs in lymphoma. Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., … Vose, J. (2016). The landscape of new drugs in lymphoma. Nature Reviews. Clinical Oncology.
  
• T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Casulo, C., O'Connor, O., Shustov, A., Fanale, M., Friedberg, J. W., Leonard, J. P., … Horwitz, S. (2017). T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute, 109(2).
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Younes, A., HILDEN, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., … Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology .
  
• Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Tao, L., Clarke, C. A., Rosenberg, A. S., Advani, R. H., Jonas, B. A., Flowers, C. R., & Keegan, T. H. M. (2017). Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. British Journal of Haematology.
  
• Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2017). Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 15(5), 608–38.
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
• 
  
•